22 completed. 22 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 22 | Completed 22 |
Follow Multiple Myeloma: new trials by email Literature Review of Multiple Myeloma trials Research Report on Multiple Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study Pomalidomide 4 mg every day in cycle 1, Pomalidomide 4 mg every other day in cycle 2, Pomalidomide 2 mg every day in cycle 2 - Multiple Myeloma in Relapse, Multiple Myeloma | Phase 4 | Completed | Amsterdam UMC, location VUmc | 12 | 2022-12-01 | 2025-04-22 |
| Home Based Daratumumab Administration for Patients With Multiple Myeloma Daratumumab and Hyaluronidase-fihj, Questionnaire Administration, Quality-of-Life Assessment - Plasma Cell Myeloma | Phase 4 | Completed | Thomas Jefferson University | 20 | 2022-11-08 | 2025-11-21 |
| Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC Transplantation Melphalan Hydrochloride for Injection - Multiple Myeloma | Phase 4 | Completed | CASI Pharmaceuticals (China) Co., Ltd. | 67 | 2020-07-24 | 2024-05-23 |
| Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients Ixazomib, Lenalidomide - Multiple Myeloma | Phase 4 | Completed | Peking Union Medical College Hospital | 211 | 2019-09-24 | 2024-08-01 |
| Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma Drug: Carfilzomib + Dexamethasone, Drug: Carfilzomib + Lenalidomide + Dexamethasone - Relapsed Refractory Multiple Myeloma | Phase 4 | Completed | Amgen | 101 | 2019-09-16 | 2026-05-11 |
| A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent Daratumumab - Multiple Myeloma | Phase 4 | Completed | Johnson & Johnson Private Limited | 150 | 2019-06-10 | 2025-02-03 |
| Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents Vaccination with pneumococcal conjugate vaccine (PCV13), Standard Antibacterial Prophylaxis - Multiple Myeloma, Pneumococcal Infection | Phase 4 | Completed | Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology | 36 | 2018-07-01 | 2022-08-31 |
| Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Apixaban - Venous Thromboembolism, Multiple Myeloma | Phase 4 | Completed | Gregory Piazza | 50 | 2018-02-28 | 2019-12-17 |
| Prolonged Protection From Bone Disease in Multiple Myeloma Zoledronic acid - Multiple Myeloma | Phase 4 | Completed | Thomas Lund | 158 | 2015-01-01 | 2023-02-17 |
| A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma Bortezomib - Multiple Myeloma | Phase 4 | Completed | Johnson & Johnson Taiwan Ltd | 18 | 2014-12-01 | 2016-07-11 |
| Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma Autologous peripheral blood stem cell transplant, Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 4 | Completed | Columbia University | 60 | 2012-09-01 | 2020-02-05 |
| Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse zoledronic acid, No treatment control - Multiple Myeloma | Phase 4 | Completed | PETHEMA Foundation | 103 | 2010-04-01 | 2020-04-06 |
| Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants zoledronic acid - Multiple Myeloma | Phase 4 | Completed | Novartis Pharmaceuticals | 121 | 2007-11-07 | 2021-05-26 |
| Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma Bortezomib, Thalidomide - Multiple Myeloma | Phase 4 | Completed | PETHEMA Foundation | 40 | 2007-01-01 | 2011-09-19 |
| Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases Zoledronic acid - Bone Neoplasms | Phase 4 | Completed | Novartis Pharmaceuticals | 73 | 2006-12-01 | 2017-02-27 |
| PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation Kepivance (Palifermin) - Non-Hodgkin's Lymphoma, Multiple Myeloma | Phase 4 | Completed | Swedish Orphan Biovitrum | 145 | 2006-04-01 | 2014-11-03 |
| Stage I Multiple Myeloma Treatment zometa - Multiple Myeloma | Phase 4 | Completed | Centre Hospitalier Universitaire de Nice | 89 | 2004-12-01 | 2024-04-12 |
| A Multiple Myeloma Trial in Patients With Bone Metastases zoledronic acid - Multiple Myeloma | Phase 4 | Completed | Novartis Pharmaceuticals | 179 | 2004-10-01 | 2011-06-29 |
| FREE Study - Fracture Reduction Evaluation Balloon Kyphoplasty - Osteopenia, Osteoporosis | Phase 4 | Completed | Medtronic Spine LLC | 300 | 2003-02-01 | 2017-12-08 |
| Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions zoledronic acid - Breast Cancer, Multiple Myeloma | Phase 4 | Completed | Novartis | 500 | 2001-10-01 | 2012-02-01 |
Showing 20 of 22. Sign in to see all of them.
Bone Neoplasms (2) · Breast Neoplasms (2) · Lymphoma, Non-Hodgkin (2) · Prostatic Neoplasms (2) · Recurrence (2) · Anemia (1) · Back Pain (1) · Blast Crisis (1) · Bone Diseases, Metabolic (1) · Burkitt Lymphoma (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Febrile Neutropenia (1) · Graft vs Host Disease (1) · Hodgkin Disease (1)
Blood Protein Disorders (22) · Cardiovascular Diseases (22) · Hematologic Diseases (22) · Hemic and Lymphatic Diseases (22) · Hemorrhagic Disorders (22) · Hemostatic Disorders (22) · Immune System Diseases (22) · Immunoproliferative Disorders (22) · Lymphoproliferative Disorders (22) · Neoplasms (22) · Neoplasms by Histologic Type (22) · Paraproteinemias (22) · Vascular Diseases (22) · Neoplasms, Plasma Cell (21) · Pathological Conditions, Signs and Symptoms (5)
Zoledronic Acid (7) · Bortezomib (3) · Lenalidomide (3) · Cyclophosphamide (2) · Dexamethasone (2) · Filgrastim (2) · Melphalan (2) · daratumumab (2) · Antilymphocyte Serum (1) · Calcium Dobesilate (1) · Fibroblast Growth Factor 7 (1) · Granulocyte Colony-Stimulating Factor (1) · Hematopoietic Stem Cell Mobilization (1) · Injections (1) · Interviews as Topic (1)
Novartis Pharmaceuticals (3) · PETHEMA Foundation (2) · Amgen (1) · Amsterdam UMC, location VUmc (1) · CASI Pharmaceuticals (China) Co., Ltd. (1) · Centre Hospitalier Universitaire de Nice (1) · Columbia University (1) · Gregory Piazza (1) · Johnson & Johnson Private Limited (1) · Johnson & Johnson Taiwan Ltd (1) · Medtronic Spine LLC (1) · Millennium Pharmaceuticals, Inc. (1) · Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology (1) · Novartis (1) · Peking Union Medical College Hospital (1)
United States (9) · China (2) · India (2) · Spain (2) · Australia (1) · Belarus (1) · Denmark (1) · France (1) · Netherlands (1) · Taiwan (1)
Adam R Binder, MD (1) · Anatoly Uss, MD/PhD (1) · Barry R. Meisenberg, MD (1) · Ian Walters, M.D. (1) · Junling Zhuang, MD (1) · Kaiyan Liu (1) · Sonja Zweegman, MD PhD (1) · Suzanne Lentzsch, MD (1) · Thomas LunD, MD Ph.D. (1)
PMID 19246088, PMID 21912321, PMID 22443312, PMID 23446769, PMID 26069291, PMID 26644410, PMID 32418789, PMID 34582035, PMID 38116642, PMID 40396505
2014 (1)